$OMED Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in OncoMed Pharmaceuticals Inc.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in OncoMed Pharmaceuticals Inc. Get notifications about new insider transactions in OncoMed Pharmaceuticals Inc for free.
Page: < prev 1 2 3 4 5 6 6 next >
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Feb 26 2015 | OMED | OncoMed Pharmaceut ... | Gould Terry P | Director | Buy | J | 0.00 | 17,775 | 0 | 44,872 | 27.1 K to 44.9 K (+65.60 %) |
Feb 26 2015 | OMED | OncoMed Pharmaceut ... | Gould Terry P | Director | Buy | J | 0.00 | 3,555 | 0 | 9,107 | 5.6 K to 9.1 K (+64.03 %) |
Feb 26 2015 | OMED | OncoMed Pharmaceut ... | Gould Terry P | Director | Buy | J | 0.00 | 26,762 | 0 | 68,224 | 41.5 K to 68.2 K (+64.55 %) |
Feb 26 2015 | OMED | OncoMed Pharmaceut ... | Gould Terry P | Director | Buy | J | 0.00 | 8,499 | 0 | 21,665 | 13.2 K to 21.7 K (+64.55 %) |
Feb 26 2015 | OMED | OncoMed Pharmaceut ... | Gould Terry P | Director | Buy | J | 0.00 | 11,135 | 0 | 28,386 | 17.3 K to 28.4 K (+64.55 %) |
Feb 26 2015 | OMED | OncoMed Pharmaceut ... | Gould Terry P | Director | Buy | J | 0.00 | 27,218 | 0 | 57,764 | 30.5 K to 57.8 K (+89.10 %) |
Feb 26 2015 | OMED | OncoMed Pharmaceut ... | Gould Terry P | Director | Buy | J | 0.00 | 2,432 | 0 | 4,863 | 2.4 K to 4.9 K (+100.04 %) |
Feb 26 2015 | OMED | OncoMed Pharmaceut ... | Gould Terry P | Director | Buy | J | 0.00 | 782 | 0 | 1,564 | 782 to 1.6 K (+100.00 %) |
Feb 26 2015 | OMED | OncoMed Pharmaceut ... | Gould Terry P | Director | Buy | J | 0.00 | 1,166 | 0 | 2,332 | 1.2 K to 2.3 K (+100.00 %) |
Feb 26 2015 | OMED | OncoMed Pharmaceut ... | Gould Terry P | Director | Buy | J | 0.00 | 19,667 | 0 | 39,334 | 19.7 K to 39.3 K (+100.00 %) |
Feb 26 2015 | OMED | OncoMed Pharmaceut ... | Gould Terry P | Director | Buy | J | 0.00 | 14,119 | 0 | 28,237 | 14.1 K to 28.2 K (+100.01 %) |
Feb 26 2015 | OMED | OncoMed Pharmaceut ... | Gould Terry P | Director | Buy | J | 0.00 | 18,278 | 0 | 36,556 | 18.3 K to 36.6 K (+100.00 %) |
Feb 26 2015 | OMED | OncoMed Pharmaceut ... | Gould Terry P | Director | Buy | J | 0.00 | 43,022 | 0 | 86,043 | 43 K to 86 K (+100.00 %) |
Feb 19 2015 | OMED | OncoMed Pharmaceut ... | Gurney Austin | See Remarks | Sell | S | 26.37 | 4,000 | 105,493 | 74,134 | 78.1 K to 74.1 K (-5.12 %) |
Feb 12 2015 | OMED | OncoMed Pharmaceut ... | Dupont Jakob | SVP & Chief Medical ... | Option Exercise | M | 4.56 | 1,500 | 6,840 | 161,937 | |
Feb 12 2015 | OMED | OncoMed Pharmaceut ... | Dupont Jakob | SVP & Chief Medical ... | Sell | S | 24.23 | 1,500 | 36,351 | 21,620 | 23.1 K to 21.6 K (-6.49 %) |
Feb 12 2015 | OMED | OncoMed Pharmaceut ... | Dupont Jakob | SVP & Chief Medical ... | Buy | M | 4.56 | 1,500 | 6,840 | 23,120 | 21.6 K to 23.1 K (+6.94 %) |
Feb 09 2015 | OMED | OncoMed Pharmaceut ... | Hoey Timothy | SVP, Cancer Biology | Option Exercise | M | 1.43 | 7,500 | 10,725 | 35,263 | |
Feb 09 2015 | OMED | OncoMed Pharmaceut ... | Hoey Timothy | SVP, Cancer Biology | Sell | S | 22.83 | 7,500 | 171,239 | 49,945 | 57.4 K to 49.9 K (-13.06 %) |
Feb 09 2015 | OMED | OncoMed Pharmaceut ... | Hoey Timothy | SVP, Cancer Biology | Buy | M | 1.43 | 7,500 | 10,725 | 57,445 | 49.9 K to 57.4 K (+15.02 %) |
Feb 04 2015 | OMED | OncoMed Pharmaceut ... | Lewicki John A. | EVP & Chief Scienti ... | Option Exercise | M | 1.43 | 4,000 | 5,720 | 40,277 | |
Feb 04 2015 | OMED | OncoMed Pharmaceut ... | Lewicki John A. | EVP & Chief Scienti ... | Sell | S | 22.49 | 4,000 | 89,951 | 20,000 | 24 K to 20 K (-16.67 %) |
Feb 04 2015 | OMED | OncoMed Pharmaceut ... | Lewicki John A. | EVP & Chief Scienti ... | Buy | M | 1.43 | 4,000 | 5,720 | 24,000 | 20 K to 24 K (+20.00 %) |
Jan 22 2015 | OMED | OncoMed Pharmaceut ... | LASERSOHN JACK W | Director | Buy | J | 0.00 | 17,995 | 0 | 22,210 | 4.2 K to 22.2 K (+426.93 %) |
Jan 21 2015 | OMED | OncoMed Pharmaceut ... | Gurney Austin | See Remarks | Sell | S | 23.69 | 100 | 2,369 | 78,134 | 78.2 K to 78.1 K (-0.13 %) |
Jan 21 2015 | OMED | OncoMed Pharmaceut ... | Gurney Austin | See Remarks | Sell | S | 22.85 | 3,900 | 89,107 | 78,234 | 82.1 K to 78.2 K (-4.75 %) |
Jan 14 2015 | OMED | OncoMed Pharmaceut ... | Dupont Jakob | SVP & Chief Medical ... | Option Exercise | M | 4.56 | 1,500 | 6,840 | 163,437 | |
Jan 14 2015 | OMED | OncoMed Pharmaceut ... | Dupont Jakob | SVP & Chief Medical ... | Sell | S | 26.62 | 400 | 10,648 | 21,620 | 22 K to 21.6 K (-1.82 %) |
Jan 14 2015 | OMED | OncoMed Pharmaceut ... | Dupont Jakob | SVP & Chief Medical ... | Sell | S | 25.63 | 1,100 | 28,188 | 22,020 | 23.1 K to 22 K (-4.76 %) |
Jan 14 2015 | OMED | OncoMed Pharmaceut ... | Dupont Jakob | SVP & Chief Medical ... | Buy | M | 4.56 | 1,500 | 6,840 | 23,120 | 21.6 K to 23.1 K (+6.94 %) |
Jan 13 2015 | OMED | OncoMed Pharmaceut ... | Gould Terry P | Director | Buy | J | 0.00 | 17,775 | 0 | 27,097 | 9.3 K to 27.1 K (+190.68 %) |
Jan 13 2015 | OMED | OncoMed Pharmaceut ... | Gould Terry P | Director | Buy | J | 0.00 | 3,555 | 0 | 5,552 | 2 K to 5.6 K (+178.02 %) |
Jan 13 2015 | OMED | OncoMed Pharmaceut ... | Gould Terry P | Director | Buy | J | 0.00 | 26,761 | 0 | 41,462 | 14.7 K to 41.5 K (+182.04 %) |
Jan 13 2015 | OMED | OncoMed Pharmaceut ... | Gould Terry P | Director | Buy | J | 0.00 | 8,498 | 0 | 13,166 | 4.7 K to 13.2 K (+182.05 %) |
Jan 13 2015 | OMED | OncoMed Pharmaceut ... | Gould Terry P | Director | Buy | J | 0.00 | 11,134 | 0 | 17,251 | 6.1 K to 17.3 K (+182.02 %) |
Jan 13 2015 | OMED | OncoMed Pharmaceut ... | Gould Terry P | Director | Buy | J | 0.00 | 27,217 | 0 | 30,546 | 3.3 K to 30.5 K (+817.57 %) |
Jan 13 2015 | OMED | OncoMed Pharmaceut ... | Gould Terry P | Director | Buy | J | 0.00 | 2,431 | 0 | 2,431 | 0 to 2.4 K |
Jan 13 2015 | OMED | OncoMed Pharmaceut ... | Gould Terry P | Director | Buy | J | 0.00 | 782 | 0 | 782 | 0 to 782 |
Jan 13 2015 | OMED | OncoMed Pharmaceut ... | Gould Terry P | Director | Buy | J | 0.00 | 1,166 | 0 | 1,166 | 0 to 1.2 K |
Jan 13 2015 | OMED | OncoMed Pharmaceut ... | Gould Terry P | Director | Buy | J | 0.00 | 19,667 | 0 | 19,667 | 0 to 19.7 K |
Jan 13 2015 | OMED | OncoMed Pharmaceut ... | Gould Terry P | Director | Buy | J | 0.00 | 14,118 | 0 | 14,118 | 0 to 14.1 K |
Jan 13 2015 | OMED | OncoMed Pharmaceut ... | Gould Terry P | Director | Buy | J | 0.00 | 18,278 | 0 | 18,278 | 0 to 18.3 K |
Jan 13 2015 | OMED | OncoMed Pharmaceut ... | Gould Terry P | Director | Buy | J | 0.00 | 43,021 | 0 | 43,021 | 0 to 43 K |
Jan 13 2015 | OMED | OncoMed Pharmaceut ... | Gould Terry P | Director | Buy | J | 0.00 | 4,575 | 0 | 9,322 | 4.7 K to 9.3 K (+96.38 %) |
Jan 13 2015 | OMED | OncoMed Pharmaceut ... | Gould Terry P | Director | Buy | J | 0.00 | 4,747 | 0 | 4,747 | 0 to 4.7 K |
Jan 13 2015 | OMED | OncoMed Pharmaceut ... | Gould Terry P | Director | Buy | J | 0.00 | 980 | 0 | 1,997 | 1 K to 2 K (+96.36 %) |
Jan 13 2015 | OMED | OncoMed Pharmaceut ... | Gould Terry P | Director | Buy | J | 0.00 | 1,017 | 0 | 1,017 | 0 to 1 K |
Jan 13 2015 | OMED | OncoMed Pharmaceut ... | Gould Terry P | Director | Buy | J | 0.00 | 1,634 | 0 | 3,329 | 1.7 K to 3.3 K (+96.40 %) |
Jan 13 2015 | OMED | OncoMed Pharmaceut ... | Gould Terry P | Director | Buy | J | 0.00 | 1,695 | 0 | 1,695 | 0 to 1.7 K |
Jan 13 2015 | OMED | OncoMed Pharmaceut ... | Gould Terry P | Director | Buy | J | 0.00 | 7,215 | 0 | 14,701 | 7.5 K to 14.7 K (+96.38 %) |
Jan 13 2015 | OMED | OncoMed Pharmaceut ... | Gould Terry P | Director | Buy | J | 0.00 | 7,486 | 0 | 7,486 | 0 to 7.5 K |
Jan 13 2015 | OMED | OncoMed Pharmaceut ... | Gould Terry P | Director | Buy | J | 0.00 | 2,291 | 0 | 4,668 | 2.4 K to 4.7 K (+96.38 %) |
Jan 13 2015 | OMED | OncoMed Pharmaceut ... | Gould Terry P | Director | Buy | J | 0.00 | 2,377 | 0 | 2,377 | 0 to 2.4 K |
Jan 13 2015 | OMED | OncoMed Pharmaceut ... | Gould Terry P | Director | Buy | J | 0.00 | 3,002 | 0 | 6,117 | 3.1 K to 6.1 K (+96.37 %) |
Jan 13 2015 | OMED | OncoMed Pharmaceut ... | Gould Terry P | Director | Buy | J | 0.00 | 3,115 | 0 | 3,115 | 0 to 3.1 K |
Jan 13 2015 | OMED | OncoMed Pharmaceut ... | ROOT JONATHAN D | Director | Buy | J | 0.00 | 712 | 0 | 63,950 | 63.2 K to 64 K (+1.13 %) |
Jan 13 2015 | OMED | OncoMed Pharmaceut ... | Lasky Laurence | Director | Buy | J | 0.00 | 1,449 | 0 | 1,449 | 0 to 1.4 K |
Jan 13 2015 | OMED | OncoMed Pharmaceut ... | LASERSOHN JACK W | Director | Buy | J | 0.00 | 16,634 | 0 | 820,904 | 804.3 K to 820.9 K (+2.07 %) |
Jan 13 2015 | OMED | OncoMed Pharmaceut ... | LASERSOHN JACK W | Director | Buy | J | 0.00 | 68,479 | 0 | 1,757,771 | 1.7 M to 1.8 M (+4.05 %) |
Jan 07 2015 | OMED | OncoMed Pharmaceut ... | Dupont Jakob | SVP & Chief Medical ... | Option Exercise | M | 4.56 | 7,500 | 34,200 | 164,937 | |
Jan 07 2015 | OMED | OncoMed Pharmaceut ... | Dupont Jakob | SVP & Chief Medical ... | Sell | S | 23.00 | 7,500 | 172,500 | 21,620 | 29.1 K to 21.6 K (-25.76 %) |
Jan 07 2015 | OMED | OncoMed Pharmaceut ... | Dupont Jakob | SVP & Chief Medical ... | Buy | M | 4.56 | 7,500 | 34,200 | 29,120 | 21.6 K to 29.1 K (+34.69 %) |
Jan 05 2015 | OMED | OncoMed Pharmaceut ... | Lewicki John A. | EVP & Chief Scienti ... | Option Exercise | M | 1.43 | 4,000 | 5,720 | 44,277 | |
Jan 05 2015 | OMED | OncoMed Pharmaceut ... | Lewicki John A. | EVP & Chief Scienti ... | Sell | S | 22.79 | 400 | 9,116 | 20,000 | 20.4 K to 20 K (-1.96 %) |
Jan 05 2015 | OMED | OncoMed Pharmaceut ... | Lewicki John A. | EVP & Chief Scienti ... | Sell | S | 22.03 | 3,600 | 79,293 | 20,400 | 24 K to 20.4 K (-15.00 %) |
Jan 05 2015 | OMED | OncoMed Pharmaceut ... | Lewicki John A. | EVP & Chief Scienti ... | Buy | M | 1.43 | 4,000 | 5,720 | 24,000 | 20 K to 24 K (+20.00 %) |
Jan 02 2015 | OMED | OncoMed Pharmaceut ... | Pollard-Knight Denise | Director | Sell | S | 21.66 | 3,799 | 82,300 | 1,943,509 | 1.9 M to 1.9 M (-0.20 %) |
Dec 30 2014 | OMED | OncoMed Pharmaceut ... | Pollard-Knight Denise | Director | Sell | S | 21.65 | 5,510 | 119,286 | 1,947,308 | 2 M to 1.9 M (-0.28 %) |
Dec 30 2014 | OMED | OncoMed Pharmaceut ... | Pollard-Knight Denise | Director | Sell | S | 21.62 | 9,902 | 214,048 | 1,952,818 | 2 M to 2 M (-0.50 %) |
Dec 30 2014 | OMED | OncoMed Pharmaceut ... | Pollard-Knight Denise | Director | Sell | S | 21.65 | 2,195 | 47,516 | 1,962,720 | 2 M to 2 M (-0.11 %) |
Dec 23 2014 | OMED | OncoMed Pharmaceut ... | Pollard-Knight Denise | Director | Sell | S | 21.71 | 20,654 | 448,310 | 1,964,915 | 2 M to 2 M (-1.04 %) |
Dec 22 2014 | OMED | OncoMed Pharmaceut ... | Hager Alicia J. | VP & General Counse ... | Option Exercise | A | 21.18 | 35,000 | 741,300 | 35,000 | |
Dec 22 2014 | OMED | OncoMed Pharmaceut ... | Hoey Timothy | SVP, Cancer Biology | Option Exercise | A | 21.18 | 50,000 | 1,059,000 | 50,000 | |
Dec 22 2014 | OMED | OncoMed Pharmaceut ... | Patel Sunil | See Remarks | Option Exercise | A | 21.18 | 50,000 | 1,059,000 | 50,000 | |
Dec 22 2014 | OMED | OncoMed Pharmaceut ... | HASTINGS PAUL J | Chairman & CEO | Option Exercise | A | 21.18 | 140,000 | 2,965,200 | 140,000 | |
Dec 22 2014 | OMED | OncoMed Pharmaceut ... | Lewicki John A. | EVP & Chief Scienti ... | Option Exercise | A | 21.18 | 50,000 | 1,059,000 | 50,000 | |
Dec 22 2014 | OMED | OncoMed Pharmaceut ... | Dupont Jakob | SVP & Chief Medical ... | Option Exercise | A | 21.18 | 50,000 | 1,059,000 | 50,000 | |
Dec 22 2014 | OMED | OncoMed Pharmaceut ... | Gurney Austin | See Remarks | Option Exercise | A | 21.18 | 50,000 | 1,059,000 | 50,000 | |
Dec 19 2014 | OMED | OncoMed Pharmaceut ... | ROOT JONATHAN D | Director | Sell | S | 21.05 | 4,390 | 92,423 | 9,509 | 13.9 K to 9.5 K (-31.59 %) |
Dec 19 2014 | OMED | OncoMed Pharmaceut ... | ROOT JONATHAN D | Director | Sell | S | 21.05 | 8,662 | 182,361 | 18,758 | 27.4 K to 18.8 K (-31.59 %) |
Dec 19 2014 | OMED | OncoMed Pharmaceut ... | Gurney Austin | See Remarks | Sell | S | 20.00 | 4,000 | 80,000 | 82,134 | 86.1 K to 82.1 K (-4.64 %) |
Dec 10 2014 | OMED | OncoMed Pharmaceut ... | Pollard-Knight Denise | Director | Sell | S | 21.77 | 7,940 | 172,889 | 1,985,569 | 2 M to 2 M (-0.40 %) |
Dec 10 2014 | OMED | OncoMed Pharmaceut ... | Pollard-Knight Denise | Director | Sell | S | 21.78 | 23,273 | 506,970 | 1,993,509 | 2 M to 2 M (-1.15 %) |
Dec 10 2014 | OMED | OncoMed Pharmaceut ... | Pollard-Knight Denise | Director | Sell | S | 21.68 | 1,727 | 37,435 | 2,016,782 | 2 M to 2 M (-0.09 %) |
Dec 05 2014 | OMED | OncoMed Pharmaceut ... | Pollard-Knight Denise | Director | Sell | S | 22.10 | 755 | 16,686 | 2,018,509 | 2 M to 2 M (-0.04 %) |
Dec 05 2014 | OMED | OncoMed Pharmaceut ... | Pollard-Knight Denise | Director | Sell | S | 21.58 | 24,245 | 523,265 | 2,019,264 | 2 M to 2 M (-1.19 %) |
Dec 03 2014 | OMED | OncoMed Pharmaceut ... | Lewicki John A. | EVP & Chief Scienti ... | Option Exercise | M | 1.43 | 4,000 | 5,720 | 48,277 | |
Dec 03 2014 | OMED | OncoMed Pharmaceut ... | Lewicki John A. | EVP & Chief Scienti ... | Sell | S | 21.19 | 4,000 | 84,752 | 20,000 | 24 K to 20 K (-16.67 %) |
Dec 03 2014 | OMED | OncoMed Pharmaceut ... | Lewicki John A. | EVP & Chief Scienti ... | Buy | M | 1.43 | 4,000 | 5,720 | 24,000 | 20 K to 24 K (+20.00 %) |
Nov 19 2014 | OMED | OncoMed Pharmaceut ... | Gurney Austin | See Remarks | Sell | S | 20.16 | 4,000 | 80,659 | 86,134 | 90.1 K to 86.1 K (-4.44 %) |
Nov 07 2014 | OMED | OncoMed Pharmaceut ... | Hoey Timothy | SVP, Cancer Biology | Option Exercise | M | 1.43 | 2,500 | 3,575 | 42,763 | |
Nov 07 2014 | OMED | OncoMed Pharmaceut ... | Hoey Timothy | SVP, Cancer Biology | Sell | S | 19.51 | 2,500 | 48,766 | 49,945 | 52.4 K to 49.9 K (-4.77 %) |
Nov 07 2014 | OMED | OncoMed Pharmaceut ... | Hoey Timothy | SVP, Cancer Biology | Buy | M | 1.43 | 2,500 | 3,575 | 52,445 | 49.9 K to 52.4 K (+5.01 %) |
Nov 05 2014 | OMED | OncoMed Pharmaceut ... | Lewicki John A. | EVP & Chief Scienti ... | Option Exercise | M | 1.43 | 4,000 | 5,720 | 52,277 | |
Nov 05 2014 | OMED | OncoMed Pharmaceut ... | Lewicki John A. | EVP & Chief Scienti ... | Gift | G | 0.00 | 602 | 0 | 83,530 | 82.9 K to 83.5 K (+0.73 %) |
Nov 05 2014 | OMED | OncoMed Pharmaceut ... | Lewicki John A. | EVP & Chief Scienti ... | Sell | S | 20.45 | 4,000 | 81,818 | 20,000 | 24 K to 20 K (-16.67 %) |
Nov 05 2014 | OMED | OncoMed Pharmaceut ... | Lewicki John A. | EVP & Chief Scienti ... | Buy | M | 1.43 | 4,000 | 5,720 | 24,000 | 20 K to 24 K (+20.00 %) |
Nov 05 2014 | OMED | OncoMed Pharmaceut ... | Lewicki John A. | EVP & Chief Scienti ... | Gift | G | 0.00 | 602 | 0 | 20,000 | 20.6 K to 20 K (-2.92 %) |
Oct 30 2014 | OMED | OncoMed Pharmaceut ... | HASTINGS PAUL J | Chairman & CEO | Option Exercise | M | 1.43 | 8,385 | 11,991 | 42,738 | |
Oct 30 2014 | OMED | OncoMed Pharmaceut ... | HASTINGS PAUL J | Chairman & CEO | Option Exercise | M | 1.43 | 8,384 | 11,989 | 51,123 | |
Oct 30 2014 | OMED | OncoMed Pharmaceut ... | HASTINGS PAUL J | Chairman & CEO | Sell | S | 21.90 | 8,385 | 183,618 | 23,231 | 31.6 K to 23.2 K (-26.52 %) |
Oct 30 2014 | OMED | OncoMed Pharmaceut ... | HASTINGS PAUL J | Chairman & CEO | Buy | M | 1.43 | 8,385 | 11,991 | 31,616 | 23.2 K to 31.6 K (+36.09 %) |
Oct 30 2014 | OMED | OncoMed Pharmaceut ... | HASTINGS PAUL J | Chairman & CEO | Sell | S | 22.08 | 8,384 | 185,124 | 23,231 | 31.6 K to 23.2 K (-26.52 %) |
Oct 30 2014 | OMED | OncoMed Pharmaceut ... | HASTINGS PAUL J | Chairman & CEO | Buy | M | 1.43 | 8,384 | 11,989 | 31,615 | 23.2 K to 31.6 K (+36.09 %) |
Oct 20 2014 | OMED | OncoMed Pharmaceut ... | Gurney Austin | See Remarks | Sell | S | 20.07 | 4,000 | 80,280 | 90,134 | 94.1 K to 90.1 K (-4.25 %) |
Oct 03 2014 | OMED | OncoMed Pharmaceut ... | Gurney Austin | See Remarks | Sell | S | 20.00 | 4,000 | 80,000 | 94,134 | 98.1 K to 94.1 K (-4.08 %) |
Oct 03 2014 | OMED | OncoMed Pharmaceut ... | Lewicki John A. | EVP & Chief Scienti ... | Option Exercise | M | 1.43 | 5,809 | 8,307 | 56,277 | |
Oct 03 2014 | OMED | OncoMed Pharmaceut ... | Lewicki John A. | EVP & Chief Scienti ... | Sell | S | 20.00 | 5,809 | 116,180 | 20,602 | 26.4 K to 20.6 K (-21.99 %) |
Oct 03 2014 | OMED | OncoMed Pharmaceut ... | Lewicki John A. | EVP & Chief Scienti ... | Buy | M | 1.43 | 5,809 | 8,307 | 26,411 | 20.6 K to 26.4 K (+28.20 %) |
Sep 05 2014 | OMED | OncoMed Pharmaceut ... | LASERSOHN JACK W | Director | Buy | P | 17.50 | 170 | 2,975 | 4,215 | 4 K to 4.2 K (+4.20 %) |
Sep 05 2014 | OMED | OncoMed Pharmaceut ... | LASERSOHN JACK W | Director | Buy | P | 18.40 | 3,000 | 55,199 | 4,045 | 1 K to 4 K (+287.08 %) |
Sep 03 2014 | OMED | OncoMed Pharmaceut ... | Lewicki John A. | EVP & Chief Scienti ... | Option Exercise | M | 1.43 | 2,191 | 3,133 | 62,086 | |
Sep 03 2014 | OMED | OncoMed Pharmaceut ... | Lewicki John A. | EVP & Chief Scienti ... | Sell | S | 20.01 | 2,191 | 43,831 | 20,602 | 22.8 K to 20.6 K (-9.61 %) |
Sep 03 2014 | OMED | OncoMed Pharmaceut ... | Lewicki John A. | EVP & Chief Scienti ... | Buy | M | 1.43 | 2,191 | 3,133 | 22,793 | 20.6 K to 22.8 K (+10.63 %) |
Aug 25 2014 | OMED | OncoMed Pharmaceut ... | Gurney Austin | See Remarks | Sell | S | 20.00 | 4,000 | 80,000 | 97,532 | 101.5 K to 97.5 K (-3.94 %) |
Aug 21 2014 | OMED | OncoMed Pharmaceut ... | PAKIANATHAN DEEPIKA | Director | Buy | P | 18.98 | 201 | 3,815 | 18,940 | 18.7 K to 18.9 K (+1.07 %) |
Aug 21 2014 | OMED | OncoMed Pharmaceut ... | PAKIANATHAN DEEPIKA | Director | Buy | P | 18.98 | 21,402 | 406,171 | 1,991,602 | 2 M to 2 M (+1.09 %) |
Aug 21 2014 | OMED | OncoMed Pharmaceut ... | PAKIANATHAN DEEPIKA | Director | Buy | P | 19.00 | 429 | 8,150 | 18,739 | 18.3 K to 18.7 K (+2.34 %) |
Aug 21 2014 | OMED | OncoMed Pharmaceut ... | PAKIANATHAN DEEPIKA | Director | Buy | P | 19.00 | 45,630 | 866,847 | 1,970,200 | 1.9 M to 2 M (+2.37 %) |
Aug 21 2014 | OMED | OncoMed Pharmaceut ... | PAKIANATHAN DEEPIKA | Director | Buy | P | 18.89 | 116 | 2,191 | 18,310 | 18.2 K to 18.3 K (+0.64 %) |
Aug 21 2014 | OMED | OncoMed Pharmaceut ... | PAKIANATHAN DEEPIKA | Director | Buy | P | 18.89 | 12,425 | 234,698 | 1,924,570 | 1.9 M to 1.9 M (+0.65 %) |
Aug 19 2014 | OMED | OncoMed Pharmaceut ... | LASERSOHN JACK W | Director | Buy | P | 17.00 | 1,045 | 17,765 | 1,045 | 0 to 1 K |
Aug 12 2014 | OMED | OncoMed Pharmaceut ... | ROOT JONATHAN D | Director | Buy | J | 0.00 | 30,846 | 0 | 63,238 | 32.4 K to 63.2 K (+95.23 %) |
Aug 12 2014 | OMED | OncoMed Pharmaceut ... | ROOT JONATHAN D | Director | Sell | J | 0.00 | 285,734 | 0 | 0 | 285.7 K to 0 (-100.00 %) |
Aug 12 2014 | OMED | OncoMed Pharmaceut ... | ROOT JONATHAN D | Director | Buy | J | 0.00 | 285,734 | 0 | 285,734 | 0 to 285.7 K |
Aug 12 2014 | OMED | OncoMed Pharmaceut ... | ROOT JONATHAN D | Director | Sell | J | 0.00 | 9,046 | 0 | 19,215 | 28.3 K to 19.2 K (-32.01 %) |
Aug 12 2014 | OMED | OncoMed Pharmaceut ... | ROOT JONATHAN D | Director | Sell | J | 0.00 | 937,205 | 0 | 1,990,783 | 2.9 M to 2 M (-32.01 %) |
Aug 12 2014 | OMED | OncoMed Pharmaceut ... | PRESIDIO MANAGEMENT GROUP VIII ... | 10% Owner | Buy | J | 0.00 | 27,572 | 0 | 56,528 | 29 K to 56.5 K (+95.22 %) |
Aug 12 2014 | OMED | OncoMed Pharmaceut ... | PRESIDIO MANAGEMENT GROUP VIII ... | 10% Owner | Buy | J | 0.00 | 8,863 | 0 | 18,170 | 9.3 K to 18.2 K (+95.23 %) |
Aug 12 2014 | OMED | OncoMed Pharmaceut ... | PRESIDIO MANAGEMENT GROUP VIII ... | 10% Owner | Buy | J | 0.00 | 27,573 | 0 | 27,573 | 0 to 27.6 K |
Aug 12 2014 | OMED | OncoMed Pharmaceut ... | PRESIDIO MANAGEMENT GROUP VIII ... | 10% Owner | Buy | J | 0.00 | 33,089 | 0 | 50,471 | 17.4 K to 50.5 K (+190.36 %) |
Aug 12 2014 | OMED | OncoMed Pharmaceut ... | PRESIDIO MANAGEMENT GROUP VIII ... | 10% Owner | Buy | J | 0.00 | 27,573 | 0 | 27,573 | 0 to 27.6 K |
Aug 12 2014 | OMED | OncoMed Pharmaceut ... | PRESIDIO MANAGEMENT GROUP VIII ... | 10% Owner | Sell | J | 0.00 | 285,734 | 0 | 0 | 285.7 K to 0 (-100.00 %) |
Aug 12 2014 | OMED | OncoMed Pharmaceut ... | PRESIDIO MANAGEMENT GROUP VIII ... | 10% Owner | Buy | J | 0.00 | 285,734 | 0 | 285,734 | 0 to 285.7 K |
Aug 12 2014 | OMED | OncoMed Pharmaceut ... | PRESIDIO MANAGEMENT GROUP VIII ... | 10% Owner | Sell | J | 0.00 | 9,046 | 0 | 19,215 | 28.3 K to 19.2 K (-32.01 %) |
Aug 12 2014 | OMED | OncoMed Pharmaceut ... | PRESIDIO MANAGEMENT GROUP VIII ... | 10% Owner | Sell | J | 0.00 | 937,205 | 0 | 1,990,783 | 2.9 M to 2 M (-32.01 %) |
Aug 07 2014 | OMED | OncoMed Pharmaceut ... | Hoey Timothy | SVP, Cancer Biology | Option Exercise | M | 1.43 | 2,500 | 3,575 | 45,263 | |
Aug 07 2014 | OMED | OncoMed Pharmaceut ... | Hoey Timothy | SVP, Cancer Biology | Sell | S | 22.30 | 200 | 4,459 | 49,343 | 49.5 K to 49.3 K (-0.40 %) |
Aug 07 2014 | OMED | OncoMed Pharmaceut ... | Hoey Timothy | SVP, Cancer Biology | Sell | S | 21.61 | 2,300 | 49,697 | 49,543 | 51.8 K to 49.5 K (-4.44 %) |
Aug 07 2014 | OMED | OncoMed Pharmaceut ... | Hoey Timothy | SVP, Cancer Biology | Buy | M | 1.43 | 2,500 | 3,575 | 51,843 | 49.3 K to 51.8 K (+5.07 %) |
Aug 04 2014 | OMED | OncoMed Pharmaceut ... | Lewicki John A. | EVP & Chief Scienti ... | Option Exercise | M | 1.43 | 4,000 | 5,720 | 64,277 | |
Aug 04 2014 | OMED | OncoMed Pharmaceut ... | Lewicki John A. | EVP & Chief Scienti ... | Sell | S | 20.98 | 4,000 | 83,912 | 20,000 | 24 K to 20 K (-16.67 %) |
Aug 04 2014 | OMED | OncoMed Pharmaceut ... | Lewicki John A. | EVP & Chief Scienti ... | Buy | M | 1.43 | 4,000 | 5,720 | 24,000 | 20 K to 24 K (+20.00 %) |
Jul 30 2014 | OMED | OncoMed Pharmaceut ... | HASTINGS PAUL J | Chairman & CEO | Option Exercise | M | 1.43 | 8,385 | 11,991 | 59,507 | |
Jul 30 2014 | OMED | OncoMed Pharmaceut ... | HASTINGS PAUL J | Chairman & CEO | Option Exercise | M | 1.43 | 8,385 | 11,991 | 67,892 | |
Jul 30 2014 | OMED | OncoMed Pharmaceut ... | HASTINGS PAUL J | Chairman & CEO | Sell | S | 22.28 | 8,385 | 186,802 | 22,500 | 30.9 K to 22.5 K (-27.15 %) |
Jul 30 2014 | OMED | OncoMed Pharmaceut ... | HASTINGS PAUL J | Chairman & CEO | Buy | M | 1.43 | 8,385 | 11,991 | 30,885 | 22.5 K to 30.9 K (+37.27 %) |
Jul 30 2014 | OMED | OncoMed Pharmaceut ... | HASTINGS PAUL J | Chairman & CEO | Sell | S | 22.70 | 100 | 2,270 | 22,500 | 22.6 K to 22.5 K (-0.44 %) |
Jul 30 2014 | OMED | OncoMed Pharmaceut ... | HASTINGS PAUL J | Chairman & CEO | Sell | S | 21.93 | 8,285 | 181,666 | 22,600 | 30.9 K to 22.6 K (-26.83 %) |
Jul 30 2014 | OMED | OncoMed Pharmaceut ... | HASTINGS PAUL J | Chairman & CEO | Buy | M | 1.43 | 8,385 | 11,991 | 30,885 | 22.5 K to 30.9 K (+37.27 %) |